{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:40:22Z","timestamp":1795081222619,"version":"4.10.2"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            High\u2010intensity focused ultrasound (\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            ) is an alternative treatment option for localized prostate cancer (\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            ), which is applied for over 15 years. There are conflicting recommendations for\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            among urological societies, which can be explained by the lack of prospective controlled studies, reports on preselected patient populations and limited follow\u2010up providing little information on overall and cancer\u2010specific survival.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We report on a large, unselected consecutive patient series of patients who have undergone primary\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            for clinically localized\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            with the longest follow\u2010up in current literature. Our results improve the understanding of the oncological efficacy, morbidity and side effects of primary\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To assess the safety, functional and oncological long\u2010term outcomes of high\u2010intensity focused ultrasound (\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            ) as a primary treatment option for localized prostate cancer (\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            ).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            We conducted a retrospective single\u2010centre study on 538 consecutive patients who underwent primary\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            for clinically localized\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            between\n                            <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                            ovember 1997 and\n                            <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                            eptember 2009.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Factors assessed were: biochemical disease\u2010free survival (\n                            <jats:styled-content style=\"fixed-case\">BDFS<\/jats:styled-content>\n                            ) according to\n                            <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                            hoenix criteria (prostate\u2010specific antigen nadir + 2\u2009ng\/\n                            <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                            ); metastatic\u2010free, overall and\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            \u2010specific survival; salvage treatment; side effects; potency; and continence status.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The mean (\n                            <jats:sc>sd<\/jats:sc>\n                            ; range) follow\u2010up was 8.1 (2.9; 2.1\u201314.0) years.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The actuarial\n                            <jats:styled-content style=\"fixed-case\">BDFS<\/jats:styled-content>\n                            rates at 5 and 10 years were 81 and 61%, respectively. The 5\u2010year\n                            <jats:styled-content style=\"fixed-case\">BDFS<\/jats:styled-content>\n                            rates for low\u2010, intermediate\u2010 and high\u2010risk patients were 88, 83 and 48%, while the 10\u2010year\n                            <jats:styled-content style=\"fixed-case\">BDFS<\/jats:styled-content>\n                            rates were 71, 63 and 32%, respectively.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Metastatic disease was reported in 0.4, 5.7 and 15.4% of low\u2010, intermediate\u2010 and high\u2010risk patients, respectively.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The salvage treatment rate was 18%.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Seventy\u2010five (13.9%) patients died.\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            \u2010specific death was registered in 18 (3.3%) patients (0, 3.8 and 11% in the low\u2010, intermediate\u2010 and high\u2010risk groups, respectively).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Side effects included bladder outlet obstruction (28.3%), Grade\n                            <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                            stress urinary incontinence (13.8, 2.4 and 0.7%, respectively) and recto\u2010urethral fistula (0.7%). Preserved potency was 25.4% (in previously potent patients).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The study demonstrates the efficacy and safety of\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            for localized\n                            <jats:styled-content style=\"fixed-case\">PCa<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">HIFU<\/jats:styled-content>\n                            is a therapeutic option for patients of advanced age, in the low\u2010 or intermediate\u2010risk groups, and with a life expectancy of \u223c10 years.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11715.x","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T07:36:02Z","timestamp":1359358562000},"page":"322-329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Fourteen\u2010year oncological and functional outcomes of high\u2010intensity focused ultrasound in localized prostate cancer"],"prefix":"10.1111","volume":"112","author":[{"given":"Roman","family":"Ganzer","sequence":"first","affiliation":[{"name":"Caritas St. Josef Medical Center University of Regensburg  Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Martin","family":"Fritsche","sequence":"additional","affiliation":[{"name":"Caritas St. Josef Medical Center University of Regensburg  Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brandtner","sequence":"additional","affiliation":[{"name":"Caritas St. Josef Medical Center University of Regensburg  Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Br\u00fcndl","sequence":"additional","affiliation":[{"name":"Caritas St. Josef Medical Center University of Regensburg  Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Urology Fuerth Hospital  Fuerth Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf F.","family":"Wieland","sequence":"additional","affiliation":[{"name":"Caritas St. Josef Medical Center University of Regensburg  Regensburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Blana","sequence":"additional","affiliation":[{"name":"Department of Urology Fuerth Hospital  Fuerth Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.062"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.037"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.04.012"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01272.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.09.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.075"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07504.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0210-4806(09)74110-5"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.07.010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08518.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.12"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0628-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011967"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2265"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01678-3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23161"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02568.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.076"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2009.0607"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:15:19Z","timestamp":1761754519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11715.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11715.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,28]]},"assertion":[{"value":"2013-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}